Form 4: Ionis Pharmaceuticals EVP Eric Swayze Reports Stock Purchase

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reports the purchase of 415 shares of common stock at $28.2115 per share through the employee stock purchase plan.

Summary

• Eric Swayze, the Executive Vice President of Research at Ionis Pharmaceuticals, reported a transaction involving the company's common stock.
• On February 28, 2025, Swayze acquired 415 shares of Ionis Pharmaceuticals' common stock at a price of $28.2115 per share.
• The purchase was made under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan.
• Following the reported transaction, Swayze directly owns 48,432 shares of Ionis Pharmaceuticals' common stock.
• Swayze also indirectly owns 184 shares through his son.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. Insider buying is generally viewed positively, but the amount is not significant enough to drastically alter sentiment.

Positives

• The purchase of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates